Country: Ísrael
Tungumál: enska
Heimild: Ministry of Health
CEFONICIDE AS SODIUM
SALOMON,LEVIN & ELSTEIN LTD
J01DC06
POWDER FOR SOLUTION FOR INJECTION
CEFONICIDE AS SODIUM 1000 MG/VIAL
I.M, I.V
Required
LABORATORIO FARMACEUTICO C.T. S.R.L., ITALY
CEFONICIDE
CEFONICIDE
Treatment of serious bacterial infections caused by microorganisms susceptible to cefonicid. Studies on specimens obtained prior to therapy should be used to determine the susceptibility or the causative organisms to Cefonicid.Therapy with Cefonicid may be initiated pending results of the studies however.Treatment should be adjusted according to study findings. Cefonicid-teva is indicated in the treatment of the infections of the lower respiratory tract urinary tract skin and skin structure bone and joints. In the treatment of the above-mentioned infections the product is particularly used in weak and/or immuno-depressed patients. Surgical prophylaxis: The administration of a single 1 g. dose of Cefonicid-teva before surgery may reduce the incidence of post-operative infections caused by susceptible microorganisms in patients undergoing surgical procedures classified as contaminated or potentially contaminated or in patients in whom infection at the operative site would present a serious risk providi
2010-04-30
Cefonicid-Teva 14. 2. 2008 , RH " ע עבקנ הז ןולע טמרופ " רשואו קדבנ ונכותו תואירבה דרשמ י ." רשואמ ןולע : ראורבפ 2008 “This leaflet format has been determined by the Ministry of Health and the content thereof has been checked and approved.” Date of approval: February 2008. אפורל ןולע Physician's Package Insert ============================================================= דיצינופצ עבט ® CEFONICID TEVA ® - ---------- ---- ---------- ---- ---------- ---- ---------- ---- ---------- ---- ---------- ---- ---------- רירשה וא דירוה ךותל הקרזהל POWDER FOR INJECTION COMPOSITION Each vial contains: _Active Ingredient _ Cefonicid sodium 1.081 g Equivalent to cefonicid 1 g As powder for injectable solution. MECHANISM OF ACTION _Pharmacodynamics _ Cefonicid is a semi-synthetic broad-spectrum cephalosporin antibiotic resistant to beta-lactamases. Similarly to other cephalosporins, cefonicid exerts its antibacterial activity through the inhibition of the bacterial cell-wall synthesis. Its _ in vitro _ and _ in vivo _ activity against a wide range of Gram-positive and Gram- negative microorganisms is documented _Pharmacokinetics _ Following administration of therapeutic doses (1 g) of cefonicid to healthy volunteers, high serum concentrations are achieved (about 100 micrograms/ml following each I.M. administration), over a prolonged period of time. The half-life of cefonicid following I.V. and I.M. administration is 4.5 hours. Cefonicid is highly and reversibly protein-bound. Cefonicid is not metabolized. 99% is excreted unchanged in the urine in 24 hours. A 500 mg I.M. dose provides a high urinary concentration (384 microgram/ml) at 6-8 hours. Cefonicid reaches therapeutic concentrations in the following tissues and fluids: heart, bones, biliary tract, prostate, uterus, adipose tissue, blood, urine, bile, and in purulent and surgical wounds. Cefonicid is not indicated for the treatment of meningitis since it does not cross t Lestu allt skjalið